TY - JOUR
T1 - Management of renal osteodystrophy with 1,25(OH)2D3. I. Effects on clinical, radiographic and biochemical parameters
AU - Goldstein, D. A.
AU - Malluche, H. H.
AU - Massry, S. G.
PY - 1979
Y1 - 1979
N2 - The effects of 1,25 (OH)2D3 on the clinical symptoms, biochemical derangements and X-ray manifestations of renal osteodystrophy were evaluated in 15 dialysis patients. Long-term treatment with this metabolite produced a marked improvement or cure of the weakness and bone pain experienced by these patients. In addition, there was a rise in the serum concentrations of total and ionized calcium and phosphorus in all patients, and a fall in serum levels of iPTH in half of them. There was an inverse correlation between the rise in serum calcium and the percent fall in serum iPTH. The serum levels of alkaline phosphatase fell progressively and returned to normal only after many months of therapy. Mild hypercalcemia occurred frequently and was rapidly controlled by either reducing the dose of 1,25(OH)2D3 or discontinuing therapy. There was improvement in X-ray abnormalities in some of the patients after 6 months of therapy. The data indicate that 1,25(OH)2D3 provides an efficacious therapeutic modality for the management of the clinical and biochemical abnormalities of renal osteodystrophy.
AB - The effects of 1,25 (OH)2D3 on the clinical symptoms, biochemical derangements and X-ray manifestations of renal osteodystrophy were evaluated in 15 dialysis patients. Long-term treatment with this metabolite produced a marked improvement or cure of the weakness and bone pain experienced by these patients. In addition, there was a rise in the serum concentrations of total and ionized calcium and phosphorus in all patients, and a fall in serum levels of iPTH in half of them. There was an inverse correlation between the rise in serum calcium and the percent fall in serum iPTH. The serum levels of alkaline phosphatase fell progressively and returned to normal only after many months of therapy. Mild hypercalcemia occurred frequently and was rapidly controlled by either reducing the dose of 1,25(OH)2D3 or discontinuing therapy. There was improvement in X-ray abnormalities in some of the patients after 6 months of therapy. The data indicate that 1,25(OH)2D3 provides an efficacious therapeutic modality for the management of the clinical and biochemical abnormalities of renal osteodystrophy.
UR - http://www.scopus.com/inward/record.url?scp=0018740997&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018740997&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0018740997
SN - 0378-0392
VL - 2
SP - 35
EP - 47
JO - Mineral and Electrolyte Metabolism
JF - Mineral and Electrolyte Metabolism
IS - 1
ER -
